TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18212498
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous succinate (200 mg t.i.d. for 12 weeks)
Study: 10735703
Drug: Heparin-bonded CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded CPB
Study: 10735703
Drug: Non-heparin-bonded CPB
Normalized name: SKIN BOND NON-FLAMMABLE CEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-heparin-bonded CPB
Study: 1286498
Drug: Flumazenil (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (mean dose, 0.76 mg)
Study: 1286498
Drug: Placebo (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mean dose, 8.9 ml)
Study: 31627715
Drug: Massive Haemorrhage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massive Haemorrhage protocol including systematic early administration of tranexamic acid (TXA)
Study: 27151015
Drug: CIK cell
Normalized name: Testone CIK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIK cell infusion
Study: 25409678
Drug: Citrate 4%
Normalized name: SODIUM CITRATE 4% SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate 4% catheter lock solution
Study: 25409678
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin at a concentration of 5,000 IU/mL
Study: 21066885
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (CTG) with Shenmai Injection (SMI) and enteral nutrition
Study: 29147070
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (CTG)
Study: 8626963
Drug: Nocturnal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal oxygen therapy
Study: 21769617
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of saline
Study: 300825
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics before and after the operation
Study: 300825
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic systemic antibiotics
Study: 31286172
Drug: Arm and
Normalized name: Arm and Hammer Simply Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm and leg cycling (A&L)
Study: 28108978
Drug: Short-course intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course intravenous levofloxacin (750 mg/day for 5 days)
Study: 28108978
Drug: Conventional intravenous/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous/oral levofloxacin (500 mg/day for 7-14 days)
Study: 28108978
Drug: Short-course intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course intravenous levofloxacin (750 mg/day)
Study: 28108978
Drug: Conventional intravenous/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous/oral levofloxacin (500 mg/day)
Study: 25040296
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser (PDL) treatment (wavelength 595 nm; fluence 8 J cm(‐2); pulse duration 0.5 ms; spot size 10 mm)
Study: 24035402
Drug: Computer-assisted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted cognitive remediation therapy (CACR)
Study: 20427547
Drug: Multidimensional Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional Family Therapy-Detention to Community (MDFT-DTC)
Study: 19928509
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (IVL) 3 mg x kg(‐1) for 30 min
Study: 19928509
Drug: Saline 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 100 ml for 30 min
Study: 17703241
Drug: Budesonide-formoterol as
Normalized name: budesonide / formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-formoterol as maintenance and reliever treatment
Study: 17703241
Drug: Salmeterol-fluticasone as
Normalized name: FLUTICASONE/SALMETEROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol-fluticasone as maintenance medication plus salbutamol as needed
Study: 14718489
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone (200 mg every 3 weeks)
Study: 12761015
Drug: 2-mL volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mL volume of epidural fentanyl
Study: 12761015
Drug: 10-mL volume
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-mL volume of epidural fentanyl
Study: 12761015
Drug: 20-mL volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mL volume of epidural fentanyl
Study: 12761015
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (2-mL, 10-mL, 20-mL)
Study: 7782978
Drug: Intensive oral
Normalized name: Uricalm Intensive Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive oral hygiene training program with detailed information, self-diagnosis training, and ongoing motivation.
Study: 7782978
Drug: Shorter oral
Normalized name: SALICYLIC ACID 2 mg in 100 mL TOPICAL SHAMPOO [FYENACEL CALMING SHOOTER CELLANDIR HAIR LOSS-Shampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter oral hygiene training program without motivation and feedback.
Study: 7782978
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no motivation sessions or oral hygiene training.
Study: 488428
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg progesterone injection
Study: 31182338
Drug: Glimepiride 2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 2 mg/day
Study: 24845394
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of transdermal testosterone cream (TTC)
Study: 24845394
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of transdermal testosterone cream (TTC)
Study: 17441983
Drug: Astra Tech
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Astra Tech Single Tooth Implant (ST) with Microthread
Study: 17441983
Drug: Astra Tech
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Astra Tech TiOblast Implant (TB) without Microthread
Study: 15197140
Drug: Repaglinide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (1.5 to 12 mg/d)
Study: 15197140
Drug: Glyburide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (5 to 20 mg/d)
Study: 11443622
Drug: Induction chemoradiotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemoradiotherapy with cisplatin (60 mg/m(2) on Days 1 and 22) and etoposide (100 mg/m(2) on Days 1, 2, 3, 22, 23, 24) plus 5940 cGy radiation in 180-cGy fractions over 6 weeks
Study: 351355
Drug: Ethanol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.75 g/kg)
Study: 31342445
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) (n=24)
Study: 28835597
Drug: 10% casein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) paste applied twice a day for 36 months
Study: 28835597
Drug: Fluoridated toothpaste
Normalized name: sodium fluoride Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoridated toothpaste applied twice a day for 36 months
Study: 18393298
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of lofexidine hydrochloride (1.2 mg and 2.0 mg)
Study: 18393298
Drug: Multidose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidose of lofexidine hydrochloride (0.4 mg)
Study: 18393298
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of lofexidine hydrochloride (1.2 mg)
Study: 18393298
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of lofexidine hydrochloride (2.0 mg)
Study: 15181099
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of UAG and AG
Study: 7555620
Drug: Carbamazepine 600
Normalized name: carbamazepine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 600 mg/day
Study: 3538486
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 100 micrograms four times daily
Study: 26927662
Drug: CIMAvax-EGF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIMAvax-EGF vaccine
Study: 26927662
Drug: CIMAvax-EGF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIMAvax-EGF vaccine (per-protocol setting)
Study: 26927662
Drug: CIMAvax-EGF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIMAvax-EGF vaccine (high EGF concentration at baseline)
Study: 24360369
Drug: Tafenoquine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 50 mg plus chloroquine
Study: 24360369
Drug: Tafenoquine 100
Normalized name: tafenoquine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 100 mg plus chloroquine
Study: 24360369
Drug: Tafenoquine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 300 mg plus chloroquine
Study: 24360369
Drug: Tafenoquine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 600 mg plus chloroquine
Study: 24360369
Drug: Primaquine 15
Normalized name: primaquine 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 15 mg for 14 days plus chloroquine
Study: 24360369
Drug: Tafenoquine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 300 mg vs Chloroquine alone
Study: 24360369
Drug: Tafenoquine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 600 mg vs Chloroquine alone
Study: 18696358
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1.5 g)
Study: 12061359
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) fluids
Study: 7473116
Drug: Sterile balanced
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile balanced salt solution (control)
Study: 28364461
Drug: Armodafinil (150-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (150-250 mg)
Study: 27053145
Drug: Optimal pressure
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal pressure ulcer-preventative care group (treatment) - regular turning every 2 hours with at least 15 minutes of tissue decompression.
Study: 25124510
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) added to psychopharmacological treatment
Study: 25124510
Drug: Brief structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief structured group psychoeducational intervention added to psychopharmacological treatment
Study: 25124510
Drug: Standard clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard clinical management including psychopharmacological treatment
Study: 17244451
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) 1.0 mg once daily for 168 weeks
Study: 16279289
Drug: Open trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open trial no tablet group
Study: 9412558
Drug: 0.15 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 IU/kg rhGH daily for 3 weeks
Study: 3113223
Drug: Continuous nitroglycerin
Normalized name: nitroglycerin Extended Release Oral Tablet [Nitrocontin Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nitroglycerin patch therapy for 7 days
Study: 3113223
Drug: 12-hour-daily intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-hour-daily intermittent nitroglycerin patch therapy for 7 days
Study: 29847426
Drug: Intraarticular facet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular facet injections with bupivacaine and steroid
Study: 11943558
Drug: Hormone-guided therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone-guided therapy
Study: 6797132
Drug: Amino acid‐carbohydrate‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid‐carbohydrate‐electrolyte infusion
Study: 6797132
Drug: Carbohydrate‐electrolyte infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐electrolyte infusion
Study: 31539599
Drug: Engage (Coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engage (Coping Skills Training and Acceptance and Commitment Therapy)
Study: 25549933
Drug: Acupuncture (100%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (100% post-treatment expectations)
Study: 25549933
Drug: Acupuncture (0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (0% post-treatment expectations)
Study: 20923463
Drug: Glycerol ointment
DrugBank: Glycerin (DB09462)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycerol ointment
Study: 19465858
Drug: Conventional, nonbiologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional, nonbiologic pharmacotherapy
Study: 15374727
Drug: Sequential transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential transdermal estrogen‐progestin therapy
Study: 8295841
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of child behavioral and parental role information
Study: 3987783
Drug: Previous three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous three drug regimens (beta blocker and two other antihypertensive agents)
Study: 28910848
Drug: Misoprostol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (50 µg)
Study: 27107394
Drug: Iron tablet
Normalized name: PNV-Iron Tablet
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron tablet (ferrous sulfate, 200 mg)
Study: 27107394
Drug: Iron infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron infusion
Study: 20413516
Drug: Benfotiamine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfotiamine (900 mg/day) for 12 weeks
Study: 17047160
Drug: Insulin clamp
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin clamp at 5 mU x m(-2) x min(-1)
Study: 17047160
Drug: Insulin clamp
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin clamp at 30 mU x m(-2) x min(-1)
Study: 17047160
Drug: Insulin clamp
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin clamp at 55 mU x m(-2) x min(-1)
Study: 17047160
Drug: Insulin clamp
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin clamp at 105 mU x m(-2) x min(-1)
Study: 10908888
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (IFNbeta-1a) 30 mcg IM once weekly
Study: 8956922
Drug: Intracarotid amobarbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracarotid amobarbital procedure (IAP) with 125 mg sodium amytal injection
Study: 1372470
Drug: Topical 5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5‐fluorouracil
Study: 31320446
Drug: Efpeglenatide 1
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide 1 mg, 2 mg, 3 mg, 4 mg once weekly
Study: 31320446
Drug: Efpeglenatide ≥1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide ≥1 mg
Study: 31320446
Drug: Efpeglenatide 3
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide 3 mg, 4 mg once weekly
Study: 24678813
Drug: Goserelin, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin, 2 monthly doses (n = 18)
Study: 24678813
Drug: Goserelin, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin, 3 monthly doses (n = 18)
Study: 24678813
Drug: Control group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, no treatment (n = 32)
Study: 17180572
Drug: Hydration therapy
Normalized name: Neosporin Daily Hydration Therapy SPF 20 Lip Balm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration therapy only
Study: 9630824
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 1 gm mycophenolate mofetil
Study: 7524456
Drug: High-dose thromboplastin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thromboplastin
Study: 7524456
Drug: High-dose thrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thrombin
Study: 7524456
Drug: High-dose thromboplastin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thromboplastin and high-dose thrombin measurements
Study: 31972655
Drug: Remimazolam continuous
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam continuous intravenous infusion (5 mg/min for 5 min, 3 mg/min for 15 min, 1 mg/min for 15 min)
Study: 31972655
Drug: Remimazolam continuous
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam continuous intravenous infusion
Study: 29548834
Drug: Standardized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized oral consent and written information sheet (Group 2)
Study: 29548834
Drug: Standardized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized oral informed consent (Group 1)
Study: 23882695
Drug: Occlusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusion therapy for amblyopia (6 hours/day in MOTAS; randomized to 6 or 12 hours/day in ROTAS)
Study: 23882695
Drug: Occlusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusion therapy on weekends
Study: 23882695
Drug: Occlusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusion therapy with less frequent attendance
Study: 23882695
Drug: Occlusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusion therapy with prolonged treatment duration
Study: 23882695
Drug: Different subpopulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different subpopulations of patch day doses
Study: 18982782
Drug: Propofol TCI
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol TCI (5 ng L(‐1) remifentanil, 2.8 microg mL(‐1) propofol)
Study: 17083356
Drug: Shrimp-derived glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shrimp-derived glucosamine (1,500 mg)
Study: 17083356
Drug: Synthetic glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic glucosamine (1,500 mg)
Study: 11881630
Drug: Clenching without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clenching without implant support
Study: 11881630
Drug: Clenching with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenching with implant support
Study: 7551918
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy combined with preoperative radiation therapy
Study: 1693711
Drug: Felodipine added
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine added to beta-blocker
Study: 1646621
Drug: Felodipine monotherapy
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine monotherapy
Study: 31934950
Drug: Fractional microablative
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional microablative CO2 laser treatment
Study: 31134707
Drug: Dietitian Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietitian Group (DG) - advised by dietitians in six weekly face-to-face behavioural therapy sessions
Study: 25814318
Drug: Pinocembrin 20-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinocembrin 20-150 mg single ascending doses
Study: 25814318
Drug: Pinocembrin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinocembrin 60 mg multiple doses
Study: 23479384
Drug: Cetuximab (week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (week 1: 400 mg/m²; subsequent weeks: 250 mg/m²) plus cisplatin (100 mg/m², day 1) and 5-fluorouracil (1000 mg/m²/day, 24-h infusion, days 1-4)
Study: 21849487
Drug: Reduced-dose bortezomib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose bortezomib, thalidomide plus dexamethasone (vtD)
Study: 15480324
Drug: Levocetirizine 5
Normalized name: Levocetirizine 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 5 mg/d
Study: 11709567
Drug: Combined-modality therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality therapy (CMT) consisting of three cycles of doxorubicin and vinblastine followed by subtotal lymphoid irradiation (STLI)
Study: 12698396
Drug: Heparin-coated extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated extracorporeal circuit
Study: 8441570
Drug: Intranasal midazolam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal midazolam, 0.4 mg/kg
Study: 31789965
Drug: Protective ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective ventilation (Low tidal volume of 6 ml/kg predicted body weight during two-lung ventilation and 3 ml/kg predicted body weight during one-lung ventilation with 5 cmH2O positive end-expiratory pressure)
Study: 31789965
Drug: Conventional ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ventilation (Intermediate tidal volume of 10 ml/kg predicted body weight during two-lung ventilation and 5 ml/kg predicted body weight during one-lung ventilation with no positive end-expiratory pressure)